Wehave screened toyocamycin as an inhibitor of phosphatidylinositol kinase. It inhibited the enzyme ofA431 cell membranewith an IC50 of 3.3 fig/ml Adenosine and formycin A also inhibited the enzyme, but other 6 related nucleosides did not. Although orobol and 2,3-dihydroxybenzaldehyde that inhibit phosphatidylinositol kinase inhibited in situ phosphatidylinositol turnover, toyocamycin didnot.
Phosphatidylinositol turnover is considered to be implicated in the cellular response to mitogens1) and transformation by oncogenes such as ras2\ src3), erbB*\ fms and /^5). Phosphatidylinositol kinase is one of the key regulatory enzymes involved in the pathway of phosphatidylinositol turnover. Therefore, we are sceening inhibitors of phosphatidylinositol kinase from microorganisms to study the biochemical role of the enzyme. Wehave developed a new assay system for phosphatidylinositol kinase using a small silica gel column, and have Recently found that orobol and 2,3-dihydroxybenzoic acid from microorganisms inhibit the enzyme6). In the course of this screening program, we have isolated toyocamycin from a culture nitrate of a Streptomyces strain. Toyocamycinis knownas an antifungal antibiotic7). This paper reports inhibition of phosphatidylinositol kinase by toyocamycin and other related nucleoside antibiotics. In addition, we have studied effects of toyocamycin, orobol and 2,3-dihydroxybenzaldehyde, a more effective analogue of 2,3-dihydroxybenzoic acid, on in situ phosphatidylinositol turnover.
Materials and Methods

Materials
Sangivamycin, tubercidin, formycins A and B, and oxanosine were isolated from microorganisms in the Institute of Microbial Chemistry. SH-formycin (7-deamino-7-mercaptoformycin) was a kind gift from Meiji Seika Kaisha, Ltd. Adenosine and inosine were purchased from Sigma Chemical Company.
[y-32P]ATP and myo-[3H]inositol were purchased from DuPont-New England Nuclear. A43 1 cell line was kindly supplied by Dr. S. Kawai, Institute of Medical Science, University of Tokyo.
Isolation of Toyocamycin
The Streptomyces strain MI698-50F1 was cultured in media containing glycerol 2.0%, soy bean meal 1.5%, K2HPO40.1% and CoCl2-6H2O 0.0005%. The medium was adjusted to pH 6.2 with 1 m KH2PO4
prior to the addition of silicon oil as antifoam and the fermentation was allowed to proceed for 8 days at 28°C on a rotary shaker. The broth nitrate (3.6 liters) was extracted with 1-BuOH (3.6 liters). The extract was concentrated to dryness and the residue (3.9g) was treated with MeOH.The soluble portion was mixed with silica gel (7 g) and applied to a silica gel column (100 g) for chromatography. The column was washed with a mixture of CHC13and MeOH(10 : 1) and the active fraction was eluted with a mixture of CHC13and MeOH(5 : 1). The crude material (400mg) was dissolved in a small amount of DMFand 1 587 chromatographed on Sephadex with MeOH. After concentration of the active fractions to dryness, the residue was crystallized from MeOHto give the purified compound (49mg). Structure determination and spectroscopic analysis revealed that it was identical to toyocamycin.
Phosphatidylinositol
Kinase Assay
Enzymeassay in vitro was carried out as described previously6). The reaction mixture of phosphatidylinositol, membrane fraction of A431 cells and [y-32P]ATP with or without inhibitors was incubated in 20 mM4-2-(hydroxyethyl)-l -piperazineethanesulfonic acid (HEPES) buffer (pH 7.2) at 20°C. The reaction was stopped by addition ofa mixture ofCHC13, MeOHand 1 n HC1 (4 : 1 : 2). After vortexing, the lower phase was taken and applied to a packed silica gel column for separating phosphorylated lipid and unreacted [y-32P]ATP. Then, phosphorylated lipid was eluted with a mixture of CHC13, MeOHand 4n NH4OH(9 : 7 : 2) and counted for radioactivity.
In situ Phosphatidylinositol
Turnover Assay A43 1 cells (3 x 1 05 cells/well) plated on 35-mm plastic wells were grown in Dulbecco's modified Eagle's medium supplemented with 5% calf serum for 16 hours. The cells were pre-incubated in lml of HEPES-buffered saline (HBS) (HEPES 20him, NaCl 150mM, KC1 5him, CaCl2 l mM, MgCl2 lmM and glucose 0. 1 %, pH 7.4) containing myo-[3H]inositol (1 /iCi/ml) at 37°C for 30 minutes, then, an inhibitor and epidermal growth factor (EGF) (400ng/ml) were added, and the incubation was continued at 37°C for 60 minutes. The cells were washed with 2ml of 10% TCAcontaining 0.01 m sodium pyrophosphate then added by 0.5 ml of 0.5 n NaOH.After removal of the solubilized fraction, the cells remained were scraped off with rubber policeman from the dishes in 1.0ml of H2O. They were combined and counted for radioactivity. of EGF, the cells were incubated for further 120 minutes. Then, the incubation was terminated by adding ice-cold 10% HC1O4(100 jul) and the mixture was neutralized by 75 mMHEPEScontaining 1.53 m KOH.The solution was kept on ice for 15 minutes, and centrifuged at 2,000 x g for 15 minutes at 4°C. The supernatant was applied to anion-exchange column (Amprep SAX, Amersham) and eluted with 0.17m KHCO3.The sum of the labeled inositol phosphates (IP + IP2 + IP3) were measured by liquid scintillation counter.
Inositol Phosphates Formation
Results and Discussion As shown in Fig. 1 , toyocamycin inhibited phosphatidylinositol kinase with an IC50 of 3.3 jug/ml. The IC50s of adenosine and formycin A were 4.3 /jg/ml and 7.0 /zg/ml, respectively. Inosine, formycin B and SH-formycin8) did not inhibit the enzyme (IC50, > lOO^g/ml). Sangivamycin is known to inhibit purified rat brain protein kinase C competitively against ATP with an inhibition constant (Ki) value of 10 jmm9). It also inhibits autophosphorylation of EGFreceptor of the A431 cell membrane in vitro10}. Although sangivamycin and tubercidin have the same nucleoside skeleton as toyocamycin, they showed only weak inhibitory activities in our assay system (IC50, > 40 pig/m\). Inhibition of protein kinase C by toyocamycin was reported to be about 30 times weaker than that by sangivamycin10). Inhibition of tyrosine kinase by toyocamycin was also ten times weaker than that by sangivamycin10). Oxanosine was reported to inhibit ras oncogene functions in rat kidney cells transformed with a temperature-sensitive Kirsten sarcoma virus1 X). It did not inhibit phosphatidylinositol kinase at lOO /zg/ml. Thus, these results indicated that toyocamycin is an unique nucleoside antibiotic which inhibits phosphatidylinositol kinase.
As shown in Table 1 , orobol and 2,3-dihydroxybenzaldehyde inhibited EGF-stimulated incorporation Effects of phosphatidylinositol kinase inhibitors on EGF-induced inositol phosphates formation are shown in Table 2 . Orobol and 2,3-dihydroxybenzaldehyde inhibited inositol phosphates formation at 10/ig/ml, but toyocamycin did not. Since toyocamycin inhibits the growth of A431 cells with an IC50 of 2.3 ng/ml, it is considered to penetrate into the cells. Toyocamycin is weaker than orobol (IC50, 0.25 /ig/ml) or 2,3-dihydroxybenzaldehyde (IC50, 0.45//g/ml) in in vitro inhibition of phosphatidylinositol kinase. Therefore, higher concentration of toyocamycin might be necessary to inhibit phosphatidylinositol turnover in situ. It is also possible that subcellular localization of toyocamycin might be different from those of orobol and 2,3-dihydroxybenzaldehyde. The A431 cell membrane contains phosphatidylinositol-4-kinase12) which is involved in phosphatidylinositol turnover. Recently, phosphatidylinositol-3-kinase was found to be associated with platelet-derived growth factor receptor1 3' 1 4*, colony stimulating factor-1 receptor1 5) and insulin receptor1 6), and it might be more important than phosphatidylinositol-4-kinase for regulation of cell proliferation. Inhibition of phosphatidylinositol-3-kinase by toyocamycin, orobol and 2,3-dihydroxybenzaldehyde is being studied.
